Stacy R. Lindborg
President, CEO & DirectorDr. Stacy R. Lindborg, Ph.D., was Co-Chief Executive Officer of Brainstorm Cell Therapeutics Inc. since January 2023 until May 09, 2024 and serves as its Director since May 09, 2024. Dr. Lindborg joined the Brainstorm Cell Therapeutics Inc. on June 01, 2020. Dr. Lindborg was Executive VP & Chief Development Officer of Brainstorm Cell Therapeutics Inc. from January 2023 and was Head of Global Clinical Research at Brainstorm Cell Therapeutics Inc. since June 01, 2020 until November 2021. She serves as an Independent Director at Imunon, Inc. (formerly known as Celsion Corporation) since June 04, 2021 and also serves as President and Chief Executive Officer since May 13, 2024. Dr. Lindborg has the pharmaceutical industry experience with a particular focus on R&D, executive management and strategy. She has worked with biologics, small molecules and cell therapies to address a broad range of diseases and disorders, including multiple Orphan drug products, along with extensive experience in early-stage development having taken molecules from first in man studies into the clinic through approval and launch. Dr. Lindborg is an experienced healthcare professional and globally recognized medical statistician with multinational experience in R&D, regulatory, strategy development, analytics and big data. Dr. Lindborg served at Biogen Incorporated from 2012 to 2020 and was its served as Vice President for Global Analytics and Data Sciences, the global biotech that discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Her experience includes senior roles at Eli Lilly & Company and Biogen. She held several senior leadership positions, most recently Vice President, Analytics and Data Science, where she built a world class Analytics and Data Sciences team, responsible for global data as well as statistical and epidemiological support for R&D and marketed products. She served on R&D governance during a time of significant growth for Biogen and was active in guiding the firm's long-term vision for growth through analytics and by stimulating innovative development platforms to increase productivity. As the portfolio grew to tackle a diverse set of neurological diseases, Dr. Lindborg motivated novel analytic and development approaches, shaving time off novel drug approvals to globally address chronic diseases. Her accomplishments at Biogen included a leadership role in seeking, receiving and maintaining global marketing approvals for Zinbryta, Plegridy and Spinraza, all of which included novel data analytical elements. The Phase 3 Spinraza program was recognized with the prestigious 2017 Prix Galien Award Winner for Best Biotechnology Product (the biomedical industry's highest accolade). She also played a key role in the Phase 3 development program for Aducanumab in Alzheimer's disease. Prior to her roles in Biogen, from 1996 to 2012, Dr. Lindborg held positions of increasing responsibility at Eli Lilly and Company as Head of R&D strategy, she was responsible for characterizing the productivity of the portfolio and driving key R&D strategy projects including the annual R&D Long-Range Plan. In this role, she created seminal insights into R&D productivity by connecting individual drug program-based development decisions to portfolio risk practices, driving fundamental R&D decisions to increase number of drug launches. Additionally, she was Leader of Zyprexa Product Management in which she was responsible for R&D, Commercial and Manufacturing plans. She was accountable for driving market share through product differentiation, global registration and launching of an injectable form of Zyprexa, working through regulatory manufacturing inspections. She has been active in professional organizations across her career, holding numerous positions within the American Statistical Association and International Biometric Society, having been elected Fellow of the association in 2008. She serves on the Scientific Advisory Board of biotechnology and technology companies and on the Board of Directors of the Massachusetts Down Syndrome Congress. She was a Board Member to the Strategic Initiative: Women in Statistics. Dr. Lindborg was also profiled in the book "STEM Gems" (2017) as the only women from the pharmaceutical industry highlighted as a leader in science, technology, engineering and mathematics. She has authored more than fifty abstracts, 200 presentations and 45 manuscripts that have been published in peer-reviewed journals. She serves on several industry advisory boards related to statistics and biotechnology. Dr. Lindborg is a graduate of Baylor University where she received a Ph.D. and M.A. in statistics and a B.A. in psychology with a minor in mathematics.
Positions
- Company NameImunon, Inc.Stock CodeIMNNPositionPresident, CEO & DirectorColleagues
- MHMichael H. TardugnoExecutive Chairman
- DVDouglas V. FallerChief Medical Officer
- JBJoshua BlacherCFO, Principal Financial Officer & Principal Accounting Officer
- KLKristin LongobardiSenior Vice President of Strategic Operations
- FJFrederick J. FritzIndependent Director
- JEJames E. DentzerIndependent Director
- DCDavid ChereshMember of Advisory Board
